Re-defining iron deficiency in patients with heart failure

References

• Schrage B, Rübsamen N, Schulz A, et al. Iron deficiency is a common disorder in general population and independently predicts all-cause mortality: results from the Gutenberg health study. Clin Res Cardiol. 2020;109(11):1352–1357.
   PubMed Web of Science ®Google Scholar
• Ioannou GN, Rockey DC, Bryson CL, et al. Iron deficiency and gastrointestinal malignancy: a population-based cohort study. Am J Med. 2002;113(4):276e80.
   Google Scholar
• Lang AT, Johnson S, Sturm M, et al. Iron deficiency without anemia: a common yet under-recognized diagnosis in young women with heavy menstrual bleeding. Blood. 2014;124(21):3510.
   PubMedGoogle Scholar
• von Haehling S, Gremmler U, Krumm M, et al. Prevalence and clinical impact of iron deficiency and anaemia among outpatients with chronic heart failure: the PrEP registry. Clin Res Cardiol. 2017;106(6):436–443.
   PubMed Web of Science ®Google Scholar
• Klip IT, Comin-Colet J, Voors AA, et al. Iron deficiency in chronic heart failure: an international pooled analysis. Am Heart J. 2013;165(4):575–582.e3.
   PubMed Web of Science ®Google Scholar
• Anker SD, Comin Colet J, Filippatos G, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med. 2009;361(25):2436–2448.
   PubMed Web of Science ®Google Scholar
• Ponikowski P, van Veldhuisen DJ, Comin-Colet J, et al. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur Heart J. 2015;36(11):657–668.
   PubMed Web of Science ®Google Scholar
• van Veldhuisen DJ, Ponikowski P, van der Meer P, et al. Effect of ferric carboxymaltose on exercise capacity in patients with chronic heart failure and iron deficiency. Circulation. 2017;136(15):1374–1383.
   PubMed Web of Science ®Google Scholar
• Okonko DO, Grzeslo A, Witkowski T, et al. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial. J Am Coll Cardiol. 2008;51(2):103–112.
   PubMed Web of Science ®Google Scholar
• Ponikowski P, Kirwan BA, Anker SD, et al. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. Lancet. 2020;396(10266):1895–1904.
   PubMed Web of Science ®Google Scholar
• Snook J, Bhala N, Beales ILP, et al. British society of gastroenterology guidelines for the management of iron deficiency anaemia in adults. Gut. 2021;70(11):2030–2051.
   PubMedGoogle Scholar
• National Institute for Health and Care Excellence. Chronic kidney disease: assessment and management. NICE Guideline [NG203]. [updated 2021 Aug; cited 2022 Feb 10th]. Available from: https://www.nice.org.uk/guidance/ng203
   Google Scholar
• McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599–3726.
   PubMed Web of Science ®Google Scholar
• Kidney Disease Improving Global Outcomes Board Members. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl. 2012;2:279–335.
   Google Scholar
• National Kidney Foundation Kidney Disease Outcomes Quality Initiative. KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease 2006. [cited 2022 Feb 10th]. Available from: http://kidneyfoundation.cachefly.net/professionals/KDOQI/guidelines_anemia/cpr32.htm
   Google Scholar
• Locatelli F, Bárány P, Covic A, et al. Kidney disease: improving global outcomes guidelines on anaemia management in chronic kidney disease: a European renal best practice position statement. Nephrol Dial Transplant. 2013;28(6):1346–1359.
   PubMed Web of Science ®Google Scholar
• Fletcher A, Forbes A, Svenson N, et al. Guideline for the laboratory diagnosis of iron deficiency in adults (excluding pregnancy) and children. Br J Haematol. 2022;196(3):523–529.
   PubMedGoogle Scholar
• Fitzsimons S, Poppe KK, Choi Y, et al. Relationship between soluble transferrin receptor and clinical outcomes in patients with heart failure According to ejection fraction phenotype: the New Zealand PEOPLE study. J Card Fail. 2022. DOI:10.1016/j.cardfail.2021.12.018. S1071-9164(22)00003-3.
   PubMedGoogle Scholar
• Grote Beverborg N, Klip IT, Meijers WC, et al. Definition of iron deficiency based on the gold standard of bone marrow iron staining in heart failure patients. Circ Heart Fail. 2018;11(2):e004519.
   PubMed Web of Science ®Google Scholar
• Cleland JGF, Zhang J, Pellicori P, et al. Prevalence and outcomes of anemia and hematinic deficiencies in patients with chronic heart failure. JAMA Cardiol. 2016;1(5):539–547.
   PubMedGoogle Scholar
• Masini G, Graham FJ, Pellicori P, et al. Criteria for iron deficiency in patients with heart failure. J Am Coll Cardiol. 2022;79(4):341–351.
   PubMed Web of Science ®Google Scholar
• Ganz T. Systemic iron homeostasis. Physiol Rev. 2013;93:1721–1724.
   PubMed Web of Science ®Google Scholar
• Hohenberger J, Ray K, Meyer K. The biology and chemistry of high-valent iron-oxo and iron-nitrido complexes. Nat Commun. 2012;3(1):720.
   PubMedGoogle Scholar
• Kehrer JP. The Haber-Weiss reaction and mechanisms of toxicity. Toxicology. 2000;149(1):43–50.
   PubMed Web of Science ®Google Scholar
• Paul BT, Manz DH, Torti FM, et al. Mitochondria and Iron: current questions. Expert Rev Hematol. 2017;10(1):65–79.
   PubMed Web of Science ®Google Scholar
• Zimmermann MB, Hurrell RF. Nutritional iron deficiency. Lancet. 2007;370(9586):511–520.
   PubMed Web of Science ®Google Scholar
• Andrews NC. Understanding heme transport. N Engl J Med. 2005;353(23):2508–2509.
   PubMed Web of Science ®Google Scholar
• Knovich MA, Storey JA, Coffman LG, et al. Ferritin for the clinician. Blood Rev. 2009;23(3):95–104.
   PubMed Web of Science ®Google Scholar
• Torti FM, Torti SV. Regulation of ferritin genes and protein. Blood. 2002;99(10):3505–3516.
   PubMed Web of Science ®Google Scholar
• Winter WE, Bazydlo LA, Harris NS. The molecular biology of human iron metabolism. Lab Med. 2014;45(2):92–102.
   PubMedGoogle Scholar
• Crielaard BJ, Lammers T, Rivella S. Targeting iron metabolism in drug discovery and delivery. Nat Rev Drug Discov. 2017;16(6):400–423.
   PubMed Web of Science ®Google Scholar
• Dautry-Varsat A, Ciechanover A, Lodish HF. pH and the recycling of transferrin during receptor-mediated endocytosis. Proc Natl Acad Sci USA. 1983;80(8):2258–2262.
   PubMed Web of Science ®Google Scholar
• Mahroum N, Alghory A, Kiyak Z, et al. Ferritin - from iron, through inflammation and autoimmunity, to COVID-19. J Autoimmun. 2022;126:102778.
   PubMed Web of Science ®Google Scholar
• Nemeth E, Tuttle MS, Powelson J, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science. 2004;306(5704):2090–2093.
   PubMed Web of Science ®Google Scholar
• Andrews NC. Closing the iron gate. N Engl J Med. 2012;366(4):376–377.
   PubMed Web of Science ®Google Scholar
• Wulfhekel U, Düllmann J. Storage of iron in bone marrow plasma cells. Ultrastructural characterization, mobilization, and diagnostic significance. Acta Haematol. 1999;101(1):7–15.
   PubMedGoogle Scholar
• Baumgartner-Stäubli R, Beck EA. Sideroblast score: a sensitive indicator of iron deficiency and hypoproliferative anemia. Acta Haematol. 1977;57(1):24–31.
   PubMedGoogle Scholar
• Burns ER, Goldberg SN, Lawrence C, et al. Clinical utility of serum tests for iron deficiency in hospitalized patients. Am J Clin Pathol. 1990;93(2):240–245.
   PubMedGoogle Scholar
• Engel JP, Schein OD, Conley CL. Bone marrow hemosiderin does not always reflect body iron stores. Arch Intern Med. 1982;142(2):287–288.
   PubMedGoogle Scholar
• Barron B, Hoyer J, Tefferi A. A bone marrow rESArt of absent stainable iron is not diagnostic of iron deficiency. Ann Hematol. 2001;80(3):66–169.
   PubMedGoogle Scholar
• American Gastroenterological Association. Iron deficiency anemia: guidelines from the American gastroenterological association. Am Fam Physician. 2021;104(2):211–212.
   PubMedGoogle Scholar
• WHO guideline on use of ferritin concentrations to assess iron status in individuals and populations [Internet]. Geneva: World Health Organization; 2020. PMID: 33909381.
   Google Scholar
• Guyatt GH, Oxman AD, Ali M, et al. Laboratory diagnosis of iron-deficiency anemia: an overview. J Gen Intern Med. 1992;7(2):145–153.
   PubMed Web of Science ®Google Scholar
• Cook JD, Baynes RD, Skikne BS. Iron deficiency and the measurement of iron status. Nutr Res Rev. 1992;5(1):198–202.
   PubMedGoogle Scholar
• Krause JR, Stolc V. Serum ferritin and bone marrow iron stores. I. Correlation with absence of iron in biopsy specimens. Am J Clin Pathol. 1979;72(5):817–820.
   PubMedGoogle Scholar
• Cassat JE, Skaar EP. Iron in infection and immunity. Cell Host Microbe. 2013;13(5):509–519.
   PubMed Web of Science ®Google Scholar
• Kernan KF, Carcillo JA. Hyperferritinemia and inflammation. Int Immunol. 2017;29(9):401–409.
   PubMed Web of Science ®Google Scholar
• Nakamura T, Naguro I, Ichijo H. Iron homeostasis and iron-regulated ROS in cell death, senescence and human diseases. Biochim Biophys Acta Gen Subj. 2019;1863(9):1398–1409.
   PubMed Web of Science ®Google Scholar
• Fahmy M, Young SP. Modulation of iron metabolism in monocyte cell line U937 by inflammatory cytokines: changes in transferrin uptake, iron handling and ferritin mRNA. Biochem J. 1993;296(Pt 1):175–181.
   PubMedGoogle Scholar
• Zandman-Goddard G, Shoenfeld Y. Ferritin in autoimmune diseases. Autoimmun Rev. 2007;6(7):457–463.
   PubMed Web of Science ®Google Scholar
• Hulthen L, Lindstedt G, Lundberg PA, et al. Effect of a mild infection on serum ferritin concentration–clinical and epidemiological implications. Eur J Clin Nutr. 1998;52(5):376–379.
   PubMed Web of Science ®Google Scholar
• Pellicori P, Doolub G, Wong CM, et al. COVID-19 and its cardiovascular effects: a systematic review of prevalence studies. Cochrane Database Syst Rev. 2021;3(3): CD013879. DOI:10.1002/14651858.CD013879.
   PubMedGoogle Scholar
• Beilby J, Olynyk J, Ching S, et al. Transferrin index: an alternative method for calculating the iron saturation of transferrin. Clin Chem. 1992;38(10):2078–2081.
   PubMed Web of Science ®Google Scholar
• Gomme PT, McCann KB, Bertolini J. Transferrin: structure, function and potential therapeutic actions. Drug Discov Today. 2005;10(4):267–273.
   PubMed Web of Science ®Google Scholar
• Stein J, Hartmann F, Dignass AU. Diagnosis and management of iron deficiency anemia in patients with IBD. Nat Rev Gastroenterol Hepatol. 2010;7(11):599–610.
   PubMed Web of Science ®Google Scholar
• Wish JB. Assessing iron status: beyond serum ferritin and transferrin saturation. Clin J Am Soc Nephrol. 2006;1(Suppl 1):S4–8.
   PubMedGoogle Scholar
• Daude S, Remen T, Chateau T, et al. Comparative accuracy of ferritin, transferrin saturation and soluble transferrin receptor for the diagnosis of iron deficiency in inflammatory bowel disease. Aliment Pharmacol Ther. 2020;51(11):1087–1095.
   PubMed Web of Science ®Google Scholar
• Romslo I, Talstad I. Day-to-day variations in serum iron, serum iron binding capacity, serum ferritin and erythrocyte protoporphyrin concentrations in anaemic subjects. Eur J Haematol. 1988;40(1):79–82.
   PubMedGoogle Scholar
• Padhi S, Glen J, Pordes BA, et al. Guideline Development Group. Management of anaemia in chronic kidney disease: summary of updated NICE guidance. BMJ. 2015;350:h2258.
   PubMedGoogle Scholar
• Tkaczyszyn M, Comín-Colet J, Voors AA, et al. Iron deficiency and red cell indices in patients with heart failure. Eur J Heart Fail. 2018;20(1):114–122.
   PubMedGoogle Scholar
• Sierpinski R, Josiak K, Suchocki T, et al. High soluble transferrin receptor in patients with heart failure: a measure of iron deficiency and a strong predictor of mortality. Eur J Heart Fail. 2021;23(6):919–932.
   PubMed Web of Science ®Google Scholar
• Girelli D, Nemeth E, Swinkels DW. Hepcidin in the diagnosis of iron dis-orders. Blood. 2016;127(23):2809–2813.
   PubMed Web of Science ®Google Scholar
• Svenson N, Bailey J, Durairaj S, et al. A simplified diagnostic pathway for the differential diagnosis of iron deficiency anaemia and anaemia of chronic disease. Int J Lab Hematol. 2021;43(6):1644–1652.
   PubMedGoogle Scholar
• Lewis GD, Malhotra R, Hernandez AF, et al. Effect of oral iron repletion on exercise capacity in patients with heart failure with reduced ejection fraction and iron deficiency: the IRONOUT HF randomized clinical trial. JAMA. 2017;317(19):1958–1966.
   PubMed Web of Science ®Google Scholar
• Franchini M, Montagnana M, Lippi G. Hepcidin and iron metabolism: from laboratory to clinical implications. Clin Chim Acta. 2010;411(21–22):1565–1569.
   PubMedGoogle Scholar
• Stockman R. The treatment of chlorosis by iron and some other drugs. Br Med J. 1893;1(1687):881–885.
   PubMedGoogle Scholar
• Blaud P. Sur les maladies chloropiques et sur un mode de traitement specifique dones ces affections. Rev Med Fr Etrang. 1832;45:357–367.
   Google Scholar
• Mackay HMM. Anaemia in infancy: its prevalence and prevention. Arch Dis Child. 1928;3(15):116–144.
   Google Scholar
• Goetsch A, Moore C, Minnich V. Observations on the effects of massive doses of iron given intravenously to patients with hyperchromic anemia. Blood. 1946;1(2):129–142.
   PubMedGoogle Scholar
• Baird I, Padmore D. Intra-muscular iron therapy in iron deficiency anemia. Lancet. 1954;2(6845):942.
   Google Scholar
• Marchasin S, Wallerstein RO. The treatment of iron-deficiency anemia with intravenous iron dextran. Blood. 1964;23(3):354–358.
   PubMedGoogle Scholar
• Hamstra RD, Block MH, Schocket AL. Intravenous iron dextran in clinical medicine. JAMA. 1980;243(17):1726–1731.
   PubMedGoogle Scholar
• Schbacii JW, Eornv JC, Downing MR, et al. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. N EngI J Med. 1987;316:73–78.
   PubMedGoogle Scholar
• MacDougal IC, Hutton RD, Cavill I, et al. Poor response to treatment of renal anaemia with erythropoietin corrected by iron given intravenously. BMJ. 1989;299(6692):157–158.
   PubMedGoogle Scholar
• Macdougall IC, Tucker B, Thompson J, et al. A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int. 1996;50(5):1694–1699.
   PubMedGoogle Scholar
• Fishbane S, Frei GL, Maesaka J. Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. Am J Kidney Dis. 1995;26(1):41–46.
   PubMed Web of Science ®Google Scholar
• Toblli JE, Lombraña A, Duarte P, et al. Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency. J Am Coll Cardiol. 2007;50(17):1657–1665.
   PubMedGoogle Scholar
• Ebner N, Jankowska EA, Ponikowski P, et al. The impact of iron deficiency and anaemia on exercise capacity and outcomes in patients with chronic heart failure. Results from the studies investigating Co-morbidities aggravating heart failure. Int J Cardiol. 2016;205:6–12.
   PubMed Web of Science ®Google Scholar
• Bekfani T, Pellicori P, Morris D, et al. Iron deficiency in patients with heart failure with preserved ejection fraction and its association with reduced exercise capacity, muscle strength and quality of life. Clin Res Cardiol. 2019;108(2):203–211.
   PubMedGoogle Scholar
• Yeo TJ, Yeo PS, Ching‐Chiew WR, et al. Iron deficiency in a multi‐ethnic Asian population with and without heart failure: prevalence, clinical correlates, functional significance and prognosis. Eur J Heart Fail. 2014;16(10):1125–1132.
   PubMedGoogle Scholar
• Okonko DO, Mandal AK, Missouris CG, et al. Disordered iron homeostasis in chronic heart failure: prevalence, predictors, and relation to anemia, exercise capacity, and survival. J Am Coll Cardiol. 2011;58(12):1241–1251.
   PubMed Web of Science ®Google Scholar
• Klip IT, Comin‐Colet J, Voors AA, et al. Iron deficiency in chronic heart failure: an international pooled analysis. Am Heart J. 2013;165(4):575–582.
   PubMed Web of Science ®Google Scholar
• Jankowska EA, Rozentryt P, Witkowska A, et al. Iron deficiency: an ominous sign in patients with systolic chronic heart failure. Eur Heart J. 2010;31(15):1872–1880.
   PubMed Web of Science ®Google Scholar
• Beale AL, Warren JL, Roberts N, et al. Iron deficiency in heart failure with preserved ejection fraction: a systematic review and meta-analysis. Open Heart. 2019;6(1):e001012.
   PubMedGoogle Scholar
• Witte KK, Desilva R, Chattopadhyay S, et al. Are hematinic deficiencies the cause of anemia in chronic heart failure? Am Heart J. 2004;147(5):924–930.
   PubMed Web of Science ®Google Scholar
• de Silva R, Rigby AS, Witte KKA, et al. Anemia, renal dysfunction and their interaction in patients with chronic heart failure. Am J Cardiol. 2006;98(3):391–398.
   PubMed Web of Science ®Google Scholar
• Windram JD, Loh PH, Rigby AS, et al. Relationship of high-sensitivity C-reactive protein to prognosis and other prognostic markers in outpatients with heart failure. Am Heart J. 2007;153(6):1048–1055.
   PubMed Web of Science ®Google Scholar
• Pellicori P, Zhang J, Cuthbert J, et al. High-sensitivity C-reactive protein in chronic heart failure: patient characteristics, phenotypes, and mode of death. Cardiovasc Res. 2020;116(1):91–100.
   PubMed Web of Science ®Google Scholar
• Opasich C, Cazzola M, Scelsi L, et al. Blunted erythropoietin production and defective iron supply for erythropoiesis as major causes of anaemia in patients with chronic heart failure. Eur Heart J. 2005;26(21):2232–2237.
   PubMedGoogle Scholar
• van der Wal HH, Grote Beverborg N, Dickstein K, et al. Iron deficiency in worsening heart failure is associated with reduced estimated protein intake, fluid retention, inflammation, and antiplatelet use. Eur Heart J. 2019;40(44):3616–3625.
   PubMedGoogle Scholar
• Androne AS, Hryniewicz K, Hudaihed A, et al. Relation of unrecognized hypervolemia in chronic heart failure to clinical status, hemodynamics, and patient outcomes. Am J Cardiol. 2004;93(10):1254–1259.
   PubMed Web of Science ®Google Scholar
• Anker SD, Voors A, Okonko D, et al. Prevalence, incidence, and prognostic value of anaemia in patients after an acute myocardial infarction: data from the OPTIMAAL trial. Eur Heart J. 2009;30(11):1331–1339.
   PubMedGoogle Scholar
• Komajda M, Anker SD, Charlesworth A, et al. The impact of new onset anaemia on morbidity and mortality in chronic heart failure: results from COMET. Eur Heart J. 2006;27(12):1440–1446.
   PubMedGoogle Scholar
• Raphael C, Briscoe C, Davies J, et al. Limitations of the New York heart association functional classification system and self-rESArted walking distances in chronic heart failure. Heart. 2007;93(4):476–482.
   PubMed Web of Science ®Google Scholar
• Goode KM, Nabb S, Cleland JG, et al. A comparison of patient and physician-rated New York heart association class in a community-based heart failure clinic. J Card Fail. 2008;14(5):379–387.
   PubMed Web of Science ®Google Scholar
• Kalra PA, Bhandari S, Saxena S, et al. A randomized trial of iron isomaltoside 1000 versus oral iron in non-dialysis-dependent chronic kidney disease patients with anaemia. Nephrol Dial Transplant. 2016;31(4):646–655.
   PubMed Web of Science ®Google Scholar
• Van Wyck DB, Roppolo M, Martinez CO, et al. A randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with nondialysis-dependent CKD. Kidney Int. 2005;68(6):2846–2856.
   PubMedGoogle Scholar
• Agarwal R, Kusek JW, Pappas MK. A randomized trial of intravenous and oral iron in chronic kidney disease. Kidney Int. 2015;88(4):905–914.
   PubMed Web of Science ®Google Scholar
• Macdougall IC, Bock AH, Carrera F, et al. FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia. Nephrol Dial Transplant. 2014;29(11):2075–2084.
   PubMed Web of Science ®Google Scholar
• Anker SD, Kirwan BA, van Veldhuisen DJ, et al. Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: an individual patient data meta-analysis. Eur J Heart Fail. 2018;20(1):125–133.
   PubMed Web of Science ®Google Scholar
• Schumacher SM, Naga Prasad SV. Tumor necrosis Factor-α in heart failure: an updated review. Curr Cardiol Rep. 2018;20(11):117.
   PubMed Web of Science ®Google Scholar
• Markousis-Mavrogenis G, Tromp J, Ouwerkerk W, et al. The clinical significance of interleukin-6 in heart failure: results from the BIOSTAT-CHF study. Eur J Heart Fail. 2019;21(8):965–973.
   PubMed Web of Science ®Google Scholar
• Adamo L, Rocha-Resende C, Prabhu SD, et al. Reappraising the role of inflammation in heart failure. Nat Rev Cardiol. 2020;17(5):269–285.
   PubMed Web of Science ®Google Scholar
• Ganz T, Nemeth E. Iron homeostasis in host defence and inflammation. Nat Rev Immunol. 2015;15(8):500–510.
   PubMed Web of Science ®Google Scholar
• Moliner P, Jankowska EA, van Veldhuisen DJ, et al. Clinical correlates and prognostic impact of impaired iron storage versus impaired iron transport in an international cohort of 1821 patients with chronic heart failure. Int J Cardiol. 2017;243:360–366.
   PubMed Web of Science ®Google Scholar
• Graham FJ, Masini G, Pellicori P, et al. Natural history and prognostic significance of iron deficiency and anaemia in ambulatory patients with chronic heart failure. Eur J Heart Fail. 2022;24(5):807–817.
   PubMedGoogle Scholar